BPC-157 (Body Protection Compound-157) — Gastric Cytoprotective Research Peptide | Klene Peptides
For Research Use Only | Not for Human or Veterinary Administration
Body Protection Compound-157 (BPC-157) is a synthetic pentadecapeptide derived from a partial sequence of a protective protein isolated from human gastric juice. Since its initial characterization in the 1990s, BPC-157 has generated a substantial body of preclinical research demonstrating tissue-protective, pro-angiogenic, and anti-inflammatory properties across multiple organ systems. Its resistance to gastric acid degradation and demonstrated systemic bioactivity following oral administration distinguish it from most research peptides of comparable molecular weight. Active research applications span musculoskeletal repair, gastrointestinal mucosal healing, neurological recovery, and wound healing acceleration. Klene Peptides supplies BPC-157 to USA research laboratories with verified purity and same-day fulfillment.
Every vial from Klene Peptides includes:
- ≥99%+ purity — verified by HPLC (High-Performance Liquid Chromatography)
- HPLC-MS (High-Performance Liquid Chromatography - Mass Spectrometry)
- Same-day shipping for all USA orders
Chemical Identity & Structural Profile
| Parameter | Value |
|---|---|
| Full Name | Body Protection Compound-157 |
| Sequence (1-letter) | GEPPPGKPADDAGLV |
| Sequence (3-letter) | Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val |
| Amino Acid Count | 15 (pentadecapeptide) |
| Molecular Formula | C₆₂H₉₈N₁₆O₂₂ |
| Molecular Weight | 1,419.55 g/mol |
| CAS Number | 137525-51-0 |
| Origin | Derived from human gastric juice protective protein |
| Appearance | White lyophilized powder |
| Solubility | Water, saline, 0.1% acetic acid |
| Storage | Lyophilized: −20°C; Reconstituted: 4°C, use within 14 days |
BPC-157 is notable for its stability under physiological conditions that typically degrade peptides, including exposure to gastric acid and serum proteases. This property, combined with demonstrated systemic activity following oral administration, makes it a uniquely practical research tool for both parenteral and enteral delivery protocol comparisons.
Mechanism of Action
BPC-157’s pharmacology is pleiotropic, engaging multiple receptor systems and signaling cascades across tissue types:
Primary Molecular Targets
| Target / Pathway | Mechanism | Research Context |
|---|---|---|
| VEGFR2 (KDR) | Upregulation of VEGF and receptor expression | Angiogenesis and wound vascularity studies |
| Growth hormone receptor | Sensitization of GH-dependent signaling | Tendon and bone repair research models |
| EGF receptor pathway | Epithelial growth factor signal modulation | Intestinal mucosal repair |
| eNOS / NO synthesis | Nitric oxide production upregulation | Vascular tone and tissue perfusion studies |
| FAK/paxillin pathway | Cytoskeletal organization in endothelial cells | Endothelial migration and tube-formation assays |
| MAPK/ERK cascade | Proliferative and survival signaling | Fibroblast and tendon cell research |
| Dopaminergic modulation | D1 and D2 receptor interaction | Neurological and behavioral models |
Anti-Inflammatory Pathways
| Mechanism | Effect |
|---|---|
| COX-2 downregulation | Reduced prostaglandin synthesis |
| NF-κB suppression | Reduced transcription of IL-1β, IL-6, TNF-α |
| Oxidative stress reduction | SOD and catalase upregulation |
| Mast cell stabilization | Reduced histamine-mediated inflammatory response |
Pharmacokinetic & ADME Profile
| Parameter | Value | Notes |
|---|---|---|
| Molecular Weight | 1,419.55 g/mol | Upper range for demonstrable oral bioavailability |
| Oral Activity | Demonstrated in preclinical models | Gastric acid stable; direct mucosal action + systemic absorption |
| Routes (Research) | SC, IP, oral, intramuscular | Multiple delivery routes studied in literature |
| Plasma Half-Life | ~4–6 hours (rodent data) | Clearance by serum proteases |
| Distribution | Broad | GI tract, tendon, liver, and brain distribution demonstrated |
| Primary Metabolism | Proteolytic (serum and tissue enzymes) | No CYP450 hepatic pathway identified |
| Excretion | Renal | Metabolite clearance |
Research Applications
Musculoskeletal & Tendon Repair
BPC-157’s most extensively studied application involves tendon, ligament, and bone healing:
| Tissue Target | Observed Effect | Primary Mechanism |
|---|---|---|
| Tendon | Accelerated collagen synthesis, improved tensile strength | GH sensitization, VEGFR2 upregulation |
| Skeletal muscle | Enhanced fiber regeneration after crush injury | NO pathway, VEGF-mediated angiogenesis |
| Bone | Improved fracture healing parameters | Osteoblast proliferation signals |
| Ligament | Accelerated ligament-to-bone healing | Angiogenesis and collagen remodeling |
Gastrointestinal Healing & Mucosal Protection
| Model | Reported Outcome |
|---|---|
| Gastric ulcer (NSAID-induced) | Accelerated mucosal healing and re-epithelialization |
| IBD / colitis models | Reduced inflammation, improved barrier integrity |
| Short bowel syndrome models | Improved intestinal adaptation parameters |
| Esophageal injury | Mucosal re-epithelialization and inflammation reduction |
Neurological & CNS Research
Emerging preclinical data explores BPC-157 in:
- Traumatic brain injury models (neuroprotective downstream signaling)
- Spinal cord research (axonal growth promotion and inflammation reduction)
- Dopaminergic dysfunction models (Parkinson's-relevant behavioral studies)
- Serotonergic system modulation (depression and anxiety preclinical models)
Wound Healing & Angiogenesis
BPC-157 consistently demonstrates accelerated wound closure and improved vascular density at wound margins across multiple tissue types, attributed to VEGF/VEGFR2 upregulation and eNOS-mediated NO production enhancing local tissue perfusion.
Research Dosing Reference
For scientific reference only — not prescriptive recommendations
| Research Model | Reported Dose Range | Route | Duration |
|---|---|---|---|
| Tendon/ligament repair (rodent) | 10 mcg/kg/day | SC, IM | 7–28 days |
| Gastric ulcer model | 10–100 mcg/kg/day | IP, oral | 7–14 days |
| Colitis models | 10 mcg/kg/day | IP, oral | 7–10 days |
| Muscle crush injury | 10 mcg/kg/day | SC | 7–14 days |
| In vitro assays | 1–100 nM | Cell culture | Per experiment |
Dosing ranges derived from PMC-indexed peer-reviewed preclinical literature.
Reconstitution Reference
| Lyophilized Amount | Sterile/Bacteriostatic Water | Concentration |
|---|---|---|
| 5 mg | 2.5 mL | 2.0 mg/mL |
| 10 mg | 5.0 mL | 2.0 mg/mL |
Klene Peptides Quality Standards
Certificate of Analysis — Standard Parameters
Every batch supplied by Klene Peptides is verified against the following analytical benchmarks:
| Test | Specification | Method |
|---|---|---|
| Purity | ≥99% | HPLC (High-Performance Liquid Chromatography) |
| Molecular Identification | Confirmed | HPLC-MS (High-Performance Liquid Chromatography – Mass Spectrometry) |
| Water Content | <1.5% | — |
What Every Klene Peptides Order Includes
- Lot-specific Certificate of Analysis traceable to synthesis batch
- Verified cold-chain shipping — all orders dispatched with appropriate cold-pack packaging
- Same-day fulfillment — orders placed before cutoff ship the same business day
Ordering BPC-157 for Your Research Program
Important Research Compliance Notice
All products sold by Klene Peptides are strictly for in vitro research and laboratory investigation purposes only. BPC-157 supplied by KlenePeptides.net has not been evaluated by the FDA for human safety or efficacy. It is not approved for human or veterinary administration. Purchase, possession, and use must comply with all applicable federal, state, and local regulations. This content is intended for licensed researchers and qualified scientific personnel only.
Scientific References
- Sikiric P, et al. "Body Protection Compound-157: Pharmacology and Biochemistry." Curr Pharm Des. 2018;24(18):1990-2001.
- Chang CH, et al. "The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration." J Appl Physiol. 2011;110(3):774-80.
- Vukovic J, et al. "Stable gastric pentadecapeptide BPC 157 heals cysteamine-colitis and colon-colon anastomosis." J Physiol Pharmacol. 2009;60(1):33-40.
- Cesarec V, et al. "Pentadecapeptide BPC 157 and the esophagocutaneous fistula healing." Eur J Pharmacol. 2013;701(1-3):203-12.
- Sikiric P, et al. "Dopamine-Related Stabilization of Rat Brain Dopamine System by Stable Gastric Pentadecapeptide BPC 157." J Physiol Paris. 2016;110(4):154-164.
- Gwyer D, et al. "Gastric pentadecapeptide body protection compound BPC 157 and its role in the healing process." Int J Mol Sci. 2019;20(8):1781.
- PubChem. BPC-157. CID: 9941957. https://pubchem.ncbi.nlm.nih.gov